Biomarker panels associated with progression of renal disease in type 1 diabetes
Marco Colombo(University of Edinburgh), Helen M. Colhoun(Edinburgh Cancer Research), Carol Forsblom(University of Helsinki), Per‐Henrik Groop(University of Helsinki), Erkka Valo(University of Helsinki), Paul McKeigue(Edinburgh Cancer Research), Luke A. K. Blackbourn(Edinburgh Cancer Research), Niina Sandholm(University of Helsinki), Stuart J. McGurnaghan(University of Edinburgh), R. Neil Dalton(National Health Service), David B. Dunger(Addenbrooke's Hospital)
Cited by 55
Related Papers
Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial
|The Lancet|2004|3.8k
Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial
|The Lancet|2019|3.1k
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
|New England Journal of Medicine|2023|2.6k
Robust associations of four new chromosome regions from genome-wide analyses of type 1 diabetes
|Nature Genetics|2007|1.5k